Review



vimentin  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech vimentin
    circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related <t>proteins</t> <t>(E-cadherin,</t> N-cadherin, <t>Vimentin)</t> in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
    Vimentin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 2445 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+Antibody/pmc13050104-89-17-18
    Average 96 stars, based on 2445 article reviews
    vimentin - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma"

    Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

    Journal: Non-coding RNA Research

    doi: 10.1016/j.ncrna.2026.03.003

    circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
    Figure Legend Snippet: circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Techniques Used: Knockdown, Functional Assay, Quantitative RT-PCR, Flow Cytometry, Marker, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Derivative Assay, Co-Culture Assay, Western Blot, Migration

    circSMAD4 depletion in macrophages restrains LUAD growth and metastasis in vivo. (A) Schematic of orthotopic lung implantation and experimental metastasis models using LLC cells mixed with BMDMs expressing shNC or sh-circSMAD4. (B) Representative images of orthotopic lung tumors. (C) Tumor weight of orthotopic implants. (D) Overall survival of mice bearing orthotopic tumors. (E) Immunofluorescence showing F4/80 and circSMAD4 signals in tumor tissues. Scale bar, 50 μm. (F, G) Representative Ki-67 IHC staining and quantification in orthotopic tumors. Scale bar, 50 μm. (H) Representative bioluminescence images of lung tumor burden in the metastasis model. (I) Tumor weight in the metastasis model. (J) Overall survival of mice in the metastasis model. (K–M) Representative IHC staining and quantification of E-cadherin and vimentin in tumors. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
    Figure Legend Snippet: circSMAD4 depletion in macrophages restrains LUAD growth and metastasis in vivo. (A) Schematic of orthotopic lung implantation and experimental metastasis models using LLC cells mixed with BMDMs expressing shNC or sh-circSMAD4. (B) Representative images of orthotopic lung tumors. (C) Tumor weight of orthotopic implants. (D) Overall survival of mice bearing orthotopic tumors. (E) Immunofluorescence showing F4/80 and circSMAD4 signals in tumor tissues. Scale bar, 50 μm. (F, G) Representative Ki-67 IHC staining and quantification in orthotopic tumors. Scale bar, 50 μm. (H) Representative bioluminescence images of lung tumor burden in the metastasis model. (I) Tumor weight in the metastasis model. (J) Overall survival of mice in the metastasis model. (K–M) Representative IHC staining and quantification of E-cadherin and vimentin in tumors. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Techniques Used: In Vivo, Expressing, Immunofluorescence, Immunohistochemistry

    Related Articles

    Incubation:

    Article Title: Hydrogen Therapy Reverses Cancer‐Associated Fibroblasts Phenotypes and Remodels Stromal Microenvironment to Stimulate Systematic Anti‐Tumor Immunity
    Article Snippet: Proteins from cell lysates were separated by SDS‐PAGE and then transferred to PVDF membranes (Bio‐Rad). .. The blots were incubated with primary antibodies: anti‐FN1 (Proteintech, 15613‐1‐AP, 1:2000), anti‐COL1A1 (CST, #72 026, 1:1000), anti‐VIM (Proteintech, 10366‐1‐AP, 1:2000), anti‐NOS2 (Proteintech, 80517‐1‐RR, 1:2000), anti‐IRF1 (CST, #8478, 1:1000), and anti‐β‐Actin (CST, #3700, 1:1000) at 4 °C overnight and with secondary antibodies at RT for 1 h. Blot images were captured by ODYSSEY imaging system. .. For immunocytochemistry assay, treated CAFs were fixed with 4% paraformaldehyde, immersed into 0.3% hydrogen peroxide, blocked with 10% goat serum, and incubated with a specific primary antibody at 4 °C overnight: anti‐FN1 (Proteintech, 15613‐1‐AP, 1:200), anti‐COL1A1 (CST, #72026, 1:200), and anti‐α‐SMA (Abcam, Ab7817, 1:1000).

    Article Title: MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability.
    Article Snippet: 11 Brain metastases account for more than 50% of intracranial central nervous system tumors.. The 12 blood-brain barrier (BBB) is mainly composed of endothelial cells, which exhibit low endocytosis 13 and high efflux pumps.. Although they are connected by continuous tight junctions and serve as a 14 protective insulation, the BBB does not prevent the development of brain metastases from non-small 15 cell lung cancer (NSCLC).

    Article Title: Identification and immunological characterization of genes associated with ferroptosis in Alzheimer's disease and experimental demonstration
    Article Snippet: .. Electrophoresis conditions were 80 V for the upper gel and run for 2 Min; the lower gel was run at 120 V for 90 min. During the membrane transfer process, proteins were transferred to nitrocellulose membranes at 250 mA for 80 min. After the transfer was completed, the membrane was closed with protein-free rapid closure solution (1X; Shanghai Epizyme Biotech Co.) for 20 min at room temperature, washed three times with 20X TBS-1% Tween-20 (TBST) buffer (50 + 950 ml purified water) for 10 min each time, and incubated overnight at 4°C with the following primary antibodies: Anti-GAPDH (36 kDa; 1:10,000; cat. no. 10494-1-AP; Proteintech Group, Inc.), anti-FAM107A (17 kDa; 1:2,000; cat. no. bs-6381R; BIOSS), anti-GFAP (45 kDa; 1:1,500; cat. no. 53-9892-82; Thermo Fisher Scientific, Inc.), anti-VIM (54 kDa; 1:2,000; cat. no. 10366-1-AP; Proteintech Group, Inc.) and anti-A4GALT (35 kDa; 1:2,000; cat. no. bs-7588R; BIOSS). ..

    Article Title: Artificial intelligence learning landscape of triple-negative breast cancer uncovers new opportunities for enhancing outcomes and immunotherapy responses
    Article Snippet: .. Next, after a series of chip sample processing procedures, the corresponding primary antibodies were used for incubation in the two groups, including anti-MEI1 (Mouse, sc-515359, Santa Cruz, United States), anti-HMX1 (Rabbit, orb184221, biorbyt, United Kingdom), anti-VIM (Rabbit, 10366-1-AP, Proteintech, China), and anti-MORN3 (Rabbit, PA5-58506, ThermoFisher, United States) antibodies. .. Afterward, the incubation and tyramide signal amplification (TSA) (FITC-TSA, CY3-TSA, 594-TSA, 647-TSA, Servicebio, China) in the microarray were performed using relevant secondary antibodies (GB23301, GB23303, Servicebio, China) that were conjugated to the fluorophore.

    Imaging:

    Article Title: Hydrogen Therapy Reverses Cancer‐Associated Fibroblasts Phenotypes and Remodels Stromal Microenvironment to Stimulate Systematic Anti‐Tumor Immunity
    Article Snippet: Proteins from cell lysates were separated by SDS‐PAGE and then transferred to PVDF membranes (Bio‐Rad). .. The blots were incubated with primary antibodies: anti‐FN1 (Proteintech, 15613‐1‐AP, 1:2000), anti‐COL1A1 (CST, #72 026, 1:1000), anti‐VIM (Proteintech, 10366‐1‐AP, 1:2000), anti‐NOS2 (Proteintech, 80517‐1‐RR, 1:2000), anti‐IRF1 (CST, #8478, 1:1000), and anti‐β‐Actin (CST, #3700, 1:1000) at 4 °C overnight and with secondary antibodies at RT for 1 h. Blot images were captured by ODYSSEY imaging system. .. For immunocytochemistry assay, treated CAFs were fixed with 4% paraformaldehyde, immersed into 0.3% hydrogen peroxide, blocked with 10% goat serum, and incubated with a specific primary antibody at 4 °C overnight: anti‐FN1 (Proteintech, 15613‐1‐AP, 1:200), anti‐COL1A1 (CST, #72026, 1:200), and anti‐α‐SMA (Abcam, Ab7817, 1:1000).

    Aqueous Normal-phase Chromatography:

    Article Title: Inhibiting RhoA Activation via GDP-state Stabilization to Relieve Heart Failure
    Article Snippet: .. Primary antibodies were diluted as follows: anti-RhoA (1:1000 in TBST, 21017, NewEast), anti-RhoGDI (1:1000, Abcam, ab133248, England), Anti-RhoA-GTP (1:1000 in TBST, 26904, NewEast), anti-Collagen I (1:1000 in TBST, ab270993, Abcam), HRP-conjugated anti-α-Tubulin antibody (1:10000 in TBST, HRP-66031, Proteintech), anti-COL3(1:2000 in TBST, A0817, abclone, USA), anti-VIM(1:1000 in TBST, YP-Ab-03212, UpingBio, China), anti-SRF(1:1000 in TBST, YP-Ab-02042, UpingBio, China), anti-FN1(1:1000 in TBST, YP-Ab-17113, UpingBio, China), anti-CFN(1:1000 in TBST, YP-Ab-03106, UpingBio, China), p-CFN(1:1000 in TBST, YP-Ab-03011, UpingBio, China), HSP90 (1:10000 in TBST, 13171-1-AP, Proteintech: Chicago, USA), ANP (1:2000 in TBST, DF6497, Affinity), BNP (1:2000 in TBST, DF6902, Affinity), and MYH7 (1:2000 in TBST, DF12122, Affinity). ..

    Binding Assay:

    Article Title: MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability.
    Article Snippet: 11 Brain metastases account for more than 50% of intracranial central nervous system tumors.. The 12 blood-brain barrier (BBB) is mainly composed of endothelial cells, which exhibit low endocytosis 13 and high efflux pumps.. Although they are connected by continuous tight junctions and serve as a 14 protective insulation, the BBB does not prevent the development of brain metastases from non-small 15 cell lung cancer (NSCLC).

    Electrophoresis:

    Article Title: Identification and immunological characterization of genes associated with ferroptosis in Alzheimer's disease and experimental demonstration
    Article Snippet: .. Electrophoresis conditions were 80 V for the upper gel and run for 2 Min; the lower gel was run at 120 V for 90 min. During the membrane transfer process, proteins were transferred to nitrocellulose membranes at 250 mA for 80 min. After the transfer was completed, the membrane was closed with protein-free rapid closure solution (1X; Shanghai Epizyme Biotech Co.) for 20 min at room temperature, washed three times with 20X TBS-1% Tween-20 (TBST) buffer (50 + 950 ml purified water) for 10 min each time, and incubated overnight at 4°C with the following primary antibodies: Anti-GAPDH (36 kDa; 1:10,000; cat. no. 10494-1-AP; Proteintech Group, Inc.), anti-FAM107A (17 kDa; 1:2,000; cat. no. bs-6381R; BIOSS), anti-GFAP (45 kDa; 1:1,500; cat. no. 53-9892-82; Thermo Fisher Scientific, Inc.), anti-VIM (54 kDa; 1:2,000; cat. no. 10366-1-AP; Proteintech Group, Inc.) and anti-A4GALT (35 kDa; 1:2,000; cat. no. bs-7588R; BIOSS). ..

    Membrane:

    Article Title: Identification and immunological characterization of genes associated with ferroptosis in Alzheimer's disease and experimental demonstration
    Article Snippet: .. Electrophoresis conditions were 80 V for the upper gel and run for 2 Min; the lower gel was run at 120 V for 90 min. During the membrane transfer process, proteins were transferred to nitrocellulose membranes at 250 mA for 80 min. After the transfer was completed, the membrane was closed with protein-free rapid closure solution (1X; Shanghai Epizyme Biotech Co.) for 20 min at room temperature, washed three times with 20X TBS-1% Tween-20 (TBST) buffer (50 + 950 ml purified water) for 10 min each time, and incubated overnight at 4°C with the following primary antibodies: Anti-GAPDH (36 kDa; 1:10,000; cat. no. 10494-1-AP; Proteintech Group, Inc.), anti-FAM107A (17 kDa; 1:2,000; cat. no. bs-6381R; BIOSS), anti-GFAP (45 kDa; 1:1,500; cat. no. 53-9892-82; Thermo Fisher Scientific, Inc.), anti-VIM (54 kDa; 1:2,000; cat. no. 10366-1-AP; Proteintech Group, Inc.) and anti-A4GALT (35 kDa; 1:2,000; cat. no. bs-7588R; BIOSS). ..

    Purification:

    Article Title: Identification and immunological characterization of genes associated with ferroptosis in Alzheimer's disease and experimental demonstration
    Article Snippet: .. Electrophoresis conditions were 80 V for the upper gel and run for 2 Min; the lower gel was run at 120 V for 90 min. During the membrane transfer process, proteins were transferred to nitrocellulose membranes at 250 mA for 80 min. After the transfer was completed, the membrane was closed with protein-free rapid closure solution (1X; Shanghai Epizyme Biotech Co.) for 20 min at room temperature, washed three times with 20X TBS-1% Tween-20 (TBST) buffer (50 + 950 ml purified water) for 10 min each time, and incubated overnight at 4°C with the following primary antibodies: Anti-GAPDH (36 kDa; 1:10,000; cat. no. 10494-1-AP; Proteintech Group, Inc.), anti-FAM107A (17 kDa; 1:2,000; cat. no. bs-6381R; BIOSS), anti-GFAP (45 kDa; 1:1,500; cat. no. 53-9892-82; Thermo Fisher Scientific, Inc.), anti-VIM (54 kDa; 1:2,000; cat. no. 10366-1-AP; Proteintech Group, Inc.) and anti-A4GALT (35 kDa; 1:2,000; cat. no. bs-7588R; BIOSS). ..



    Similar Products

    vimentin  (MedChemExpress)
    94
    MedChemExpress vimentin
    Vimentin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+Antibody/pm42119668-82-46-48
    Average 94 stars, based on 1 article reviews
    vimentin - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    anti human vimentin fitc conjugated readye lease antibody  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti human vimentin fitc conjugated readye lease antibody
    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), <t>Vimentin</t> (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.
    Anti Human Vimentin Fitc Conjugated Readye Lease Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+Antibody%2C+anti-human%2C+REAdye_lease/pmc13256168-350-19-27
    Average 94 stars, based on 1 article reviews
    anti human vimentin fitc conjugated readye lease antibody - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    vimentin  (Proteintech)
    96
    Proteintech vimentin
    circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related <t>proteins</t> <t>(E-cadherin,</t> N-cadherin, <t>Vimentin)</t> in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
    Vimentin, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+Antibody/pmc13050104-89-17-18
    Average 96 stars, based on 1 article reviews
    vimentin - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    antibodies against human vimentin  (Huabio Inc)
    86
    Huabio Inc antibodies against human vimentin
    circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related <t>proteins</t> <t>(E-cadherin,</t> N-cadherin, <t>Vimentin)</t> in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.
    Antibodies Against Human Vimentin, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/anti+vimentin/pm42242136-128-8-12
    Average 86 stars, based on 1 article reviews
    antibodies against human vimentin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    vimentin  (Cell Signaling Technology Inc)
    98
    Cell Signaling Technology Inc vimentin
    MSC-mt alleviates oxidative stress and promote tissue regeneration during wound healing (A) In vivo imaging showing the spatial–temporal persistence of fluorescently labeled MSC-mt (mtH) at the wound site at indicated time point, indicating transient but sustained early presence after topical application. (B) Measurement of ATP levels in peri-wound tissues on PWD8 showed enhanced local metabolic activity following mtH treatment. n = 5 ∼ 6 per group. (C) Quantification of malondialdehyde (MDA) levels in peri-wound tissues on PWD8 indicated reduced lipid peroxidation and oxidative stress in both MSC-mt–treated wounds. n = 5 ∼ 6 per group. (D) Laser speckle contrast imaging of blood perfusion at the wound site on PWD8 showed improved microvascular perfusion following mtH treatment. n = 5 per group. (E) Representative immunofluorescence images and quantification <t>of</t> <t>CD31</t> expression in peri-wound tissues on PWD8, indicating enhanced angiogenesis in mtH–treated wounds. n = 6 per group. (F) Quantitative PCR analysis of angiogenesis-related gene expression in peri-wound tissues on PWD8, indicating transcriptional activation of pro-angiogenic programs following mtH treatment. n = 3 ∼ 5 per group. (G-H) Representative immunohistochemical staining and quantification of Col1a1 in wound tissues on PWD8, showing increased collagen synthesis and matrix remodeling in mtH–treated wounds. n = 6 per group. Scale bar = 100 μm. (I-J) Representative immunofluorescence staining and quantification of <t>Vimentin</t> and TUNEL in wound tissues on PWD8, indicating reduced fibroblast apoptosis following mtH treatment. n = 6 per group. Scale bar = 20 μm. (K-L) Representative immunofluorescence staining and quantification of Vimentin and 8-hydroxyguanosine (8-OHG) in wound tissues on PWD8, indicating attenuated oxidative DNA damage in fibroblasts following mtH treatment. n = 6 per group. Scale bar = 20 μm. Data are presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
    Vimentin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+XP+Rabbit+mAb/pmc13049664-124-17-18
    Average 98 stars, based on 1 article reviews
    vimentin - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    anti vimentin  (MedChemExpress)
    94
    MedChemExpress anti vimentin
    MSC-mt alleviates oxidative stress and promote tissue regeneration during wound healing (A) In vivo imaging showing the spatial–temporal persistence of fluorescently labeled MSC-mt (mtH) at the wound site at indicated time point, indicating transient but sustained early presence after topical application. (B) Measurement of ATP levels in peri-wound tissues on PWD8 showed enhanced local metabolic activity following mtH treatment. n = 5 ∼ 6 per group. (C) Quantification of malondialdehyde (MDA) levels in peri-wound tissues on PWD8 indicated reduced lipid peroxidation and oxidative stress in both MSC-mt–treated wounds. n = 5 ∼ 6 per group. (D) Laser speckle contrast imaging of blood perfusion at the wound site on PWD8 showed improved microvascular perfusion following mtH treatment. n = 5 per group. (E) Representative immunofluorescence images and quantification <t>of</t> <t>CD31</t> expression in peri-wound tissues on PWD8, indicating enhanced angiogenesis in mtH–treated wounds. n = 6 per group. (F) Quantitative PCR analysis of angiogenesis-related gene expression in peri-wound tissues on PWD8, indicating transcriptional activation of pro-angiogenic programs following mtH treatment. n = 3 ∼ 5 per group. (G-H) Representative immunohistochemical staining and quantification of Col1a1 in wound tissues on PWD8, showing increased collagen synthesis and matrix remodeling in mtH–treated wounds. n = 6 per group. Scale bar = 100 μm. (I-J) Representative immunofluorescence staining and quantification of <t>Vimentin</t> and TUNEL in wound tissues on PWD8, indicating reduced fibroblast apoptosis following mtH treatment. n = 6 per group. Scale bar = 20 μm. (K-L) Representative immunofluorescence staining and quantification of Vimentin and 8-hydroxyguanosine (8-OHG) in wound tissues on PWD8, indicating attenuated oxidative DNA damage in fibroblasts following mtH treatment. n = 6 per group. Scale bar = 20 μm. Data are presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
    Anti Vimentin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/Vimentin+Antibody/pmc13187529-3-0-2
    Average 94 stars, based on 1 article reviews
    anti vimentin - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    antibody targeting vimentin  (Servicebio Inc)
    86
    Servicebio Inc antibody targeting vimentin
    MSC-mt alleviates oxidative stress and promote tissue regeneration during wound healing (A) In vivo imaging showing the spatial–temporal persistence of fluorescently labeled MSC-mt (mtH) at the wound site at indicated time point, indicating transient but sustained early presence after topical application. (B) Measurement of ATP levels in peri-wound tissues on PWD8 showed enhanced local metabolic activity following mtH treatment. n = 5 ∼ 6 per group. (C) Quantification of malondialdehyde (MDA) levels in peri-wound tissues on PWD8 indicated reduced lipid peroxidation and oxidative stress in both MSC-mt–treated wounds. n = 5 ∼ 6 per group. (D) Laser speckle contrast imaging of blood perfusion at the wound site on PWD8 showed improved microvascular perfusion following mtH treatment. n = 5 per group. (E) Representative immunofluorescence images and quantification <t>of</t> <t>CD31</t> expression in peri-wound tissues on PWD8, indicating enhanced angiogenesis in mtH–treated wounds. n = 6 per group. (F) Quantitative PCR analysis of angiogenesis-related gene expression in peri-wound tissues on PWD8, indicating transcriptional activation of pro-angiogenic programs following mtH treatment. n = 3 ∼ 5 per group. (G-H) Representative immunohistochemical staining and quantification of Col1a1 in wound tissues on PWD8, showing increased collagen synthesis and matrix remodeling in mtH–treated wounds. n = 6 per group. Scale bar = 100 μm. (I-J) Representative immunofluorescence staining and quantification of <t>Vimentin</t> and TUNEL in wound tissues on PWD8, indicating reduced fibroblast apoptosis following mtH treatment. n = 6 per group. Scale bar = 20 μm. (K-L) Representative immunofluorescence staining and quantification of Vimentin and 8-hydroxyguanosine (8-OHG) in wound tissues on PWD8, indicating attenuated oxidative DNA damage in fibroblasts following mtH treatment. n = 6 per group. Scale bar = 20 μm. Data are presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
    Antibody Targeting Vimentin, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+vim/antibody+targeting+vimentin/pm42141251-53-9-17
    Average 86 stars, based on 1 article reviews
    antibody targeting vimentin - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Positive and negative control cells for both marker panels. ( A ) HeLa (white arrows): in the first panel positive for cytokeratin (CK), Vimentin (Vim), VEGF and in the second panel positive for p16INK4A, negative for PD-L1 and CD45. ( B ) T98G (red arrows): positive for Vim. ( C ) CaSki (yellow arrows): positive for CK, Vim, VEGF, PD-L1 and p16INK4A. ( D ) MCF-7 (green arrows): positive for CK. All cell lines were negative for CD45. Only hematopoietic cells showed CD45 positive staining. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and the figure was assembled using Microsoft PowerPoint.

    Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

    Techniques: Negative Control, Marker, Staining, Software

    Representative images of patient-derived DTCs with three different profiles. ( A ) DTC positive for Vim, VEGF and p16, negative for CK, PD-L1 and CD45. ( B ) CK and Vim positive while negative for VEGF, PD-L1, p16 and CD45. ( C ) DTC positive for Vim and PD-L1, negative for all other markers. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and figure was assembled using Microsoft PowerPoint.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Representative images of patient-derived DTCs with three different profiles. ( A ) DTC positive for Vim, VEGF and p16, negative for CK, PD-L1 and CD45. ( B ) CK and Vim positive while negative for VEGF, PD-L1, p16 and CD45. ( C ) DTC positive for Vim and PD-L1, negative for all other markers. Scale bar = 10 μm. Images were processed using Zeiss ZEN 3.7 software and figure was assembled using Microsoft PowerPoint.

    Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

    Techniques: Derivative Assay, Software

    Proportion of DTC Phenotypes. The majority of detected DTCs (70%, n = 174) was positive for Vimentin without CK expression, hence revealing a mesenchymal phenotype. An epithelial phenotype was found in 13% ( n = 31) of the DTCs and 15% ( n = 37) presented epithelial–mesenchymal transition (EMT)-like properties. Chart generated using Microsoft Excel.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Proportion of DTC Phenotypes. The majority of detected DTCs (70%, n = 174) was positive for Vimentin without CK expression, hence revealing a mesenchymal phenotype. An epithelial phenotype was found in 13% ( n = 31) of the DTCs and 15% ( n = 37) presented epithelial–mesenchymal transition (EMT)-like properties. Chart generated using Microsoft Excel.

    Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

    Techniques: Expressing, Generated

    Sequential multi-parameter immunofluorescent staining. After applying the first antibody panel (CK, Vim and VEGF), the slides were scanned and DTC profiles were assessed. Subsequently, releasable fluorochrome-conjugates were digested and the slides were subjected to the second antibody panel (PD-L1, p16, CD45) followed by scanning and DTC detection. Created with BioRender.com.

    Journal: International Journal of Molecular Sciences

    Article Title: Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets—A New Perspective?

    doi: 10.3390/ijms27114875

    Figure Lengend Snippet: Sequential multi-parameter immunofluorescent staining. After applying the first antibody panel (CK, Vim and VEGF), the slides were scanned and DTC profiles were assessed. Subsequently, releasable fluorochrome-conjugates were digested and the slides were subjected to the second antibody panel (PD-L1, p16, CD45) followed by scanning and DTC detection. Created with BioRender.com.

    Article Snippet: In the first round of staining, anti-human Pan-Cytokeratin APC-conjugated REAdye_lease antibody (Cat. No. 130-123-091, Miltenyi Biotech, Bergisch Gladbach, Germany), anti-human vimentin FITC-conjugated REAdye_lease antibody (Cat. No. 130-127-022, Miltenyi Biotech, Bergisch Gladbach, Germany) and anti-human VEGF PE-conjugated REAdye_lease antibody (Cat. No. 130-118-061, Miltenyi Biotech, Bergisch Gladbach, Germany) were applied.

    Techniques: Staining

    circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Journal: Non-coding RNA Research

    Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

    doi: 10.1016/j.ncrna.2026.03.003

    Figure Lengend Snippet: circSMAD4 drives tumor-educated M2-like polarization of macrophages and promotes tumor-cell aggressiveness. (A) Workflow for generating TC-hMDMs and TC-BMDMs, circSMAD4 knockdown, and downstream functional assays. (B) RT–qPCR analysis of M1-associated markers (MHC-II [HLA-DRA in TC-hMDMs; H2-Ab1 in TC-BMDMs], NOS2, and CD86) and M2-associated markers (CD163, CD206, and ARG1) in TC-hMDMs and TC-BMDMs. (C) Representative flow-cytometry histograms for HLA-DR, iNOS, CD86, CD163, CD206, and ARG1 in TC-hMDMs. Gating strategy and marker thresholds were defined based on FMO controls (see ). (D) Flow-cytometry quantification of marker-positive cells in TC-hMDMs and TC-BMDMs. (E) ELISA of IL-10, TGF-β, and iNOS in culture supernatants. (F) CCK-8 assays of A549 and LLC cells. (G) Colony-formation assays of A549 and LLC cells with quantification. (H) Bioluminescence-based growth readouts of patient-derived LUAD organoids (PDO #1 and PDO #2) after co-culture with TC-hMDMs. (I) Immunoblot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin) in A549 and LLC cells. (J) Transwell migration and invasion assays of A549 and LLC cells with quantification. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Article Snippet: Sections were incubated with primary antibodies against Ki-67 (Servicebio, Cat# GB111499 ), E-cadherin (Proteintech, Cat# 20874-1-AP), and Vimentin (Proteintech, Cat# 10366-1-AP).

    Techniques: Knockdown, Functional Assay, Quantitative RT-PCR, Flow Cytometry, Marker, Enzyme-linked Immunosorbent Assay, CCK-8 Assay, Derivative Assay, Co-Culture Assay, Western Blot, Migration

    circSMAD4 depletion in macrophages restrains LUAD growth and metastasis in vivo. (A) Schematic of orthotopic lung implantation and experimental metastasis models using LLC cells mixed with BMDMs expressing shNC or sh-circSMAD4. (B) Representative images of orthotopic lung tumors. (C) Tumor weight of orthotopic implants. (D) Overall survival of mice bearing orthotopic tumors. (E) Immunofluorescence showing F4/80 and circSMAD4 signals in tumor tissues. Scale bar, 50 μm. (F, G) Representative Ki-67 IHC staining and quantification in orthotopic tumors. Scale bar, 50 μm. (H) Representative bioluminescence images of lung tumor burden in the metastasis model. (I) Tumor weight in the metastasis model. (J) Overall survival of mice in the metastasis model. (K–M) Representative IHC staining and quantification of E-cadherin and vimentin in tumors. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Journal: Non-coding RNA Research

    Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

    doi: 10.1016/j.ncrna.2026.03.003

    Figure Lengend Snippet: circSMAD4 depletion in macrophages restrains LUAD growth and metastasis in vivo. (A) Schematic of orthotopic lung implantation and experimental metastasis models using LLC cells mixed with BMDMs expressing shNC or sh-circSMAD4. (B) Representative images of orthotopic lung tumors. (C) Tumor weight of orthotopic implants. (D) Overall survival of mice bearing orthotopic tumors. (E) Immunofluorescence showing F4/80 and circSMAD4 signals in tumor tissues. Scale bar, 50 μm. (F, G) Representative Ki-67 IHC staining and quantification in orthotopic tumors. Scale bar, 50 μm. (H) Representative bioluminescence images of lung tumor burden in the metastasis model. (I) Tumor weight in the metastasis model. (J) Overall survival of mice in the metastasis model. (K–M) Representative IHC staining and quantification of E-cadherin and vimentin in tumors. Scale bar, 50 μm. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

    Article Snippet: Sections were incubated with primary antibodies against Ki-67 (Servicebio, Cat# GB111499 ), E-cadherin (Proteintech, Cat# 20874-1-AP), and Vimentin (Proteintech, Cat# 10366-1-AP).

    Techniques: In Vivo, Expressing, Immunofluorescence, Immunohistochemistry

    MSC-mt alleviates oxidative stress and promote tissue regeneration during wound healing (A) In vivo imaging showing the spatial–temporal persistence of fluorescently labeled MSC-mt (mtH) at the wound site at indicated time point, indicating transient but sustained early presence after topical application. (B) Measurement of ATP levels in peri-wound tissues on PWD8 showed enhanced local metabolic activity following mtH treatment. n = 5 ∼ 6 per group. (C) Quantification of malondialdehyde (MDA) levels in peri-wound tissues on PWD8 indicated reduced lipid peroxidation and oxidative stress in both MSC-mt–treated wounds. n = 5 ∼ 6 per group. (D) Laser speckle contrast imaging of blood perfusion at the wound site on PWD8 showed improved microvascular perfusion following mtH treatment. n = 5 per group. (E) Representative immunofluorescence images and quantification of CD31 expression in peri-wound tissues on PWD8, indicating enhanced angiogenesis in mtH–treated wounds. n = 6 per group. (F) Quantitative PCR analysis of angiogenesis-related gene expression in peri-wound tissues on PWD8, indicating transcriptional activation of pro-angiogenic programs following mtH treatment. n = 3 ∼ 5 per group. (G-H) Representative immunohistochemical staining and quantification of Col1a1 in wound tissues on PWD8, showing increased collagen synthesis and matrix remodeling in mtH–treated wounds. n = 6 per group. Scale bar = 100 μm. (I-J) Representative immunofluorescence staining and quantification of Vimentin and TUNEL in wound tissues on PWD8, indicating reduced fibroblast apoptosis following mtH treatment. n = 6 per group. Scale bar = 20 μm. (K-L) Representative immunofluorescence staining and quantification of Vimentin and 8-hydroxyguanosine (8-OHG) in wound tissues on PWD8, indicating attenuated oxidative DNA damage in fibroblasts following mtH treatment. n = 6 per group. Scale bar = 20 μm. Data are presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.

    Journal: Materials Today Bio

    Article Title: Extracellular biogenic nanoscale mitochondria reprogram the wound microenvironment via ROS scavenging independent of cellular uptake

    doi: 10.1016/j.mtbio.2026.103023

    Figure Lengend Snippet: MSC-mt alleviates oxidative stress and promote tissue regeneration during wound healing (A) In vivo imaging showing the spatial–temporal persistence of fluorescently labeled MSC-mt (mtH) at the wound site at indicated time point, indicating transient but sustained early presence after topical application. (B) Measurement of ATP levels in peri-wound tissues on PWD8 showed enhanced local metabolic activity following mtH treatment. n = 5 ∼ 6 per group. (C) Quantification of malondialdehyde (MDA) levels in peri-wound tissues on PWD8 indicated reduced lipid peroxidation and oxidative stress in both MSC-mt–treated wounds. n = 5 ∼ 6 per group. (D) Laser speckle contrast imaging of blood perfusion at the wound site on PWD8 showed improved microvascular perfusion following mtH treatment. n = 5 per group. (E) Representative immunofluorescence images and quantification of CD31 expression in peri-wound tissues on PWD8, indicating enhanced angiogenesis in mtH–treated wounds. n = 6 per group. (F) Quantitative PCR analysis of angiogenesis-related gene expression in peri-wound tissues on PWD8, indicating transcriptional activation of pro-angiogenic programs following mtH treatment. n = 3 ∼ 5 per group. (G-H) Representative immunohistochemical staining and quantification of Col1a1 in wound tissues on PWD8, showing increased collagen synthesis and matrix remodeling in mtH–treated wounds. n = 6 per group. Scale bar = 100 μm. (I-J) Representative immunofluorescence staining and quantification of Vimentin and TUNEL in wound tissues on PWD8, indicating reduced fibroblast apoptosis following mtH treatment. n = 6 per group. Scale bar = 20 μm. (K-L) Representative immunofluorescence staining and quantification of Vimentin and 8-hydroxyguanosine (8-OHG) in wound tissues on PWD8, indicating attenuated oxidative DNA damage in fibroblasts following mtH treatment. n = 6 per group. Scale bar = 20 μm. Data are presented as mean ± SEM. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.

    Article Snippet: Sections were incubated overnight at 4 °C with primary antibodies against CD31 (Servicebio, Cat# GB120005 , 1:200), Vimentin (CST, Cat# 5741, 1:200), and 8-hydroxyguanosine (8-OHG, Rockland, Cat# 200-301-A99, 1:200).

    Techniques: In Vivo Imaging, Labeling, Activity Assay, Imaging, Immunofluorescence, Expressing, Real-time Polymerase Chain Reaction, Gene Expression, Activation Assay, Immunohistochemical staining, Staining, TUNEL Assay